my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-16-2012: Otsuka Pharmaceutical Co., Ltd. and UCB announced that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discontinue their collaboration in immunology. The companies will end their co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon transition period.
UCB is preparing to file certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour and Welfare (MHLW) in the first quarter of 2012. Positive Japanese study results, showing that certolizumab pegol was associated with significant inhibition of structural joint damage progression and significant improvements in physical function compared to placebo, were published at the recent American College of Rheumatology’s (ACR) 2011 Annual Scientific Meeting.1
The decision to discontinue its collaboration in immunology is in line with Otsuka Pharmaceutical’s clear priorities to focus in the future on CNS and oncology in its pharmaceutical business.
In December 2011, Otsuka Pharmaceutical filed rotigotine for marketing authorisation in Japan with the MHLW for the treatment of Parkinson’s disease and restless legs syndrome. In 2010, E Keppra® (levetiracetam), was approved and launched in Japan for the adjunctive treatment of partial onset seizures in adults with epilepsy which offers many patients a new option of treatment.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Otsuka Pharmaceutical Co., Ltd. and UCB announced that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discontinue their collaboration in immunology. The companies will end their co-development and co-promotion ... more
E Keppra (levetiracetam) receives regulatory approval in Japan
Otsuka Pharmaceutical Co., Ltd. and UCB announced that UCB Japan has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® (250 mg and 500 mg Tablets). E Keppra® has been approved in Japan as adjunctive therapy in the trea ... more
European Commission approves Samsca for Hyponatraemia
Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca™(tolvaptan), a selective V2-vasopressin receptor antagonist, for the t ... more
Cimzia shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitis
UCB announced positive top-line results from the phase 3 study designed to evaluate the efficacy and safety of certolizumab pegol in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS)."The ... more
UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president ... more
UCB and Oxford University announce new R&D partnership
UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will gi ... more
With a unique combination of expertise in biology and chemistry, UCB is a global biopharma focusing on severe diseases in three therapeutic areas - CNS, inflammation and oncology. more
UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more
UCB, Brussels, Belgium is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflam ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
